Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals Announces Poster Presentation at the 61st American Society of Hematology Annual Meeting and Exposition
CAMBRIDGE, Mass. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that Santiago Arroyo , M.D., Ph.D., Chief Medical Officer, will deliver a poster presentation at the upcoming 61 st American Society of Hematology (ASH) Annual Meeting and Exposition
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
CAMBRIDGE, Mass. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will webcast its presentation at two upcoming
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results
CAMBRIDGE, Mass. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today reported its financial results for the third quarter ended
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of Third Quarter 2019 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , Oct. 17, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the
View HTML
Toggle Summary Momenta Pharmaceuticals Appoints Dr. Donna Grogan to Board of Directors
CAMBRIDGE, Mass. , Sept. 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals , Inc . (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the appointment of Donna Grogan , M.D.
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results
— Launches adaptive Phase 2/3 study of nipocalimab (M281) in Warm Autoimmune Hemolytic Anemia (wAIHA), the Company’s third study of its FcRn inhibitor; top-line data expected by end of 2021 — — Company receives FDA Fast Track Designation for nipocalimab in wAIHA and HDFN — CAMBRIDGE, Mass. , Aug.
View HTML
Toggle Summary Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation
CAMBRIDGE, Mass. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, announced the launch of an adaptive Phase 2/3 clinical study for its
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Fast Track Designation for M281 (nipocalimab) in Hemolytic Disease of the Fetus and Newborn (HDFN)
CAMBRIDGE, Mass. , July 30, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that the U.S.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of Second Quarter 2019 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , July 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Settlement Agreement with Amphastar Resolving Enoxaparin Sodium Injection Litigation
CAMBRIDGE, Mass. , June 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Momenta, Sandoz AG and Amphastar Pharmaceuticals
View HTML